Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age

Abstract EN

Purpose.

To compare refractive and biometric outcomes in patients with type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of ranibizumab (IVR) versus bevacizumab (IVB), at a corrected age of 3 years.

Methods.

A retrospective case series compared cycloplegic refractive statuses and biometric statuses in patients who received either IVR or IVB for type 1 ROP, from April 2011 to April 2014.

Results.

A total of 62 eyes (33 patients) with type 1 ROP were evaluated (26 eyes in 13 IVR patients and 36 eyes in 20 IVB patients).

There were no differences in birth statuses including gestational age and birth body weight between the two groups.

The prevalence of refractive error greater than 1 D was higher in the IVB group (p=0.03), and there was a higher prevalence of high myopia (<−5.0 D, p=0.03) in the IVB group.

Comparisons in biometric finding showed that IVB patients had shallower anterior chamber depth (p=0.01).

Conclusion.

Both IVR and IVB showed low refractive errors, even followed at the corrected age of 3 years.

No difference was noted between the two groups in refractive statuses.

However, IVB was associated with shallower anterior chamber and higher prevalence of refractive error at the corrected age of 3 years.

This trial is registered with NCT03334513.